Instrumentation for the Coagulation Laboratory

  • Christopher M. Lehman
  • Catherine Thompson


International Normalize Ratio Platelet Function Activate Clotting Time Clot Lysis Clot Strength 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moreira, PL, Lansden, CC, Clark, TL. Effect of Hemopure® on prothrombin time and activated partial thromboplastin time on seven coagulation analyzers. Clin Chem 1997; 43:1792.PubMedGoogle Scholar
  2. 2.
    Mischke, R, Wolling, H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis 2000; 30:123–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Mischke, R, Menzel, D, Wolling, H. Comparison of different methods to measure fibrinogen concentration in canine plasma with respect to their sensitivity towards the fibrinogen degradation products X, Y and D. Haemostasis 2000; 30:131–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Point-of-care monitoring of anticoagulation therapy; approved guideline. CLSI document H49-A.Wayne, PA: Clinical and Laboratory Standards Institute, 2004.Google Scholar
  5. 5.
    Murray, ET, Fitzmaurice, DA, McCahon, D. Point of care testing for INR monitoring; where are we now? BMJ 2004; 127:373–8.Google Scholar
  6. 6.
    Spinler, SA, Nutescu, EA, Smythe, MA. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 2005; 39:1049–55.PubMedCrossRefGoogle Scholar
  7. 7.
    Yang, DT, Robetorye, R, Rodgers, GM. Home prothrombin time monitoring: a literature analysis. Am J Hematol 2004; 77:177–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Point-of-care connectivity; approved guideline. CLSI document POCT1-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2001.Google Scholar
  9. 9.
    Dalbert, S, Ganter, MT, Furrer, L. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices. Acta Anesthesiol Scand 2006; 50:461–468.CrossRefGoogle Scholar
  10. 10.
    Santrach, PJ. Point-of-care hematology, hemostasis, and thrombolysis testing. In: Kost, GJ, editor. Principals and practice of point-of-care testing. Philadelphia: Lippincott Williams & Wilkins, 2002:157–80.Google Scholar
  11. 11.
    Kratz, A, Van Cott, EM. Activated clotting time methods and clinical applications. Point of Care 2005; 4:90–4.Google Scholar
  12. 12.
    Salooja, N, Perry, DJ. Thromboelastography. Blood Coagul Fibrinolysis 2001; 12:327–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Khurana, S, Mattson, JC, Westley, S. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130:401–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Mousa, SA, Khurana, S, Forsythe, MS. Comparative In Vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000; 20:1162–67.PubMedGoogle Scholar
  15. 15.
    Waters, JH, Anthony, DG, Gottlieb, A. Bleeding in a patient receiving platelet aggregation inhibitors. Anesth Analg 2001; 93:878–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Horlocker, TT, Schroeder, DR. Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations. Mayo Clin Proc 1997; 72:214–19.PubMedGoogle Scholar
  17. 17.
    Rodgers, RPC, Levin, J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Hayward CPM, Harrison P, Cataneo TL, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Hayward, CPM, Harrison, P, Cattaneo, M, et al. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312–19.PubMedCrossRefGoogle Scholar
  20. 20.
    Harrison, P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130:3–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Haubelt, H, Anders, Christof, Vogt, Anette, et al. Variables influencing platelet function analyzer-100 closure times in healthy individuals. Br J Haematol 2005; 130:759–67.PubMedCrossRefGoogle Scholar
  22. 22.
    Prisco, D, Paniccia, R. Point-of-care testing of hemostasis in cardiac surgery. Thromb J 2003; 1:1–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Despotis, GJ, Joist, JH, Goodnough, LT. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997; 43:1684–96.PubMedGoogle Scholar
  24. 24.
    Carr, ME. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophy 2003; 38:55–78.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Christopher M. Lehman
  • Catherine Thompson

There are no affiliations available

Personalised recommendations